 "Cipla partners with S&D Pharma to tap Czech Republic and Slovakia")
Cipla has signed an agreement for the commercial collaboration with S&D Pharma in the Czech Republic and Slovakia. This collaboration will enable Cipla to focus on its core therapy areas, while S&D Pharma will be the key partner for generics. S&D Pharma is UK-based company which, in partnership with its local offices, represents global pharmaceutical companies and manages the promotion and distribution of their products in Central Europe.
Under the collaboration, Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head. S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years.
Frank Pieters, Head Cipla Europe, said, “We are excited to partner with S&D Pharma and believe that this collaboration will enable us to drive access in the Czech Republic and Slovakia across therapy areas in the coming years.”
Daniel Straus, CEO, S&D Pharma, said, “We are delighted to extend our cooperation with such an innovative company as Cipla and to have the opportunity to further develop the Cipla brand and portfolio in our markets. Through this collaboration we have secured a competitive and varied product pipeline for the future and very much look forward to contributing to the future success of Cipla's respiratory range.
In the near future, once the necessary regulatory and reimbursement approvals are in place, the Salmeterol-Fluticasone fixed combination will be launched in both markets under the name Fullhale. “With Fullhale we will offer in Czech Republic and Slovakia an alternative which is effective and efficient and therefore brings many advantages into a market which suffers from limited resources,” Cipla said in a pess release.
Apart from Croatia where the combination is already available under the name Duohal, Cipla recently launched the product in Germany and Sweden. In Germany, the product is distributed under the name Serroflo, whereas in Sweden the combination is launched as Salmeterol/Fluticasone Cipla.
Under the collaboration, Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head. S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years.
Frank Pieters, Head Cipla Europe, said, “We are excited to partner with S&D Pharma and believe that this collaboration will enable us to drive access in the Czech Republic and Slovakia across therapy areas in the coming years.”
Daniel Straus, CEO, S&D Pharma, said, “We are delighted to extend our cooperation with such an innovative company as Cipla and to have the opportunity to further develop the Cipla brand and portfolio in our markets. Through this collaboration we have secured a competitive and varied product pipeline for the future and very much look forward to contributing to the future success of Cipla's respiratory range.
In the near future, once the necessary regulatory and reimbursement approvals are in place, the Salmeterol-Fluticasone fixed combination will be launched in both markets under the name Fullhale. “With Fullhale we will offer in Czech Republic and Slovakia an alternative which is effective and efficient and therefore brings many advantages into a market which suffers from limited resources,” Cipla said in a pess release.
Apart from Croatia where the combination is already available under the name Duohal, Cipla recently launched the product in Germany and Sweden. In Germany, the product is distributed under the name Serroflo, whereas in Sweden the combination is launched as Salmeterol/Fluticasone Cipla.